 |
|
Clinical trial confirms novel EGFR antibody targets tumors but not normal tissues
June 06, 2006The Ludwig Institute for Cancer Research (LICR) and Life Science Pharmaceuticals (LSP) today announced the results of the first clinical trial of monoclonal antibody (mAb) 806, which demonstrate that 806 specifically targets epidermal growth factor receptor (EGFR) on a wide range of tumor types but has no uptake by normal tissues. This result is markedly different to other mAbs, which target wild-type (wt) EGFR on normal tissues.
According to Andrew M. Scott, M.D., the Director of LICR's Melbourne Centre for Clinical Sciences and principal investigator on the trial, extensive characterization of both mAb 806 and its epitope have been performed by LICR investigators in Melbourne and New York. "We have shown that the 806 antigen is not exposed on inactive wild-type EGFR, but is exposed on a transitional form of the EGFR. The epitope studies are supported by immunohistochemistry demonstrating that the 806 antibody binds to a broad range of epithelial cancers and to gliomas, but not to normal human tissues. These and other preclinical data suggest that 806 would not have the side-effects observed with other EGFR-targeting mAbs."
The 806 antibody has been licensed exclusively to LSP, which is working closely with LICR investigators to develop its commercial potential. "We think the unique targeting capabilities of 806 represent a new and exciting paradigm for cancer treatment," says James Fiore, President and CEO of LSP. "This mAb has a potent anti-tumor activity, with no targeting of normal tissues, in xenograft models, and now this clinical study has validated its target-specificity and safety in humans."
The clinical trial confirmed the excellent targeting of ch806 to cancers including squamous cell carcinomas of the lung, head and neck and skin, colorectal cancer, mesothelioma and glioma. Importantly, there was no evidence of localization of ch806 to normal tissue. No significant toxicities were observed. The results were published in the Proceedings of the American Society for Clinical Oncology's Annual Meeting being held currently in Atlanta, GA. The mAb 806 is an investigational drug and it is not approved for use in any indication in any country at this time.
Ludwig Institute for Cancer Research
The clinical trial confirmed the excellent targeting of ch806 to cancers including squamous cell carcinomas of the lung, head and neck and skin, colorectal cancer, mesothelioma and glioma. Importantly, there was no evidence of localization of ch806 to normal tissue. No significant toxicities were observed. The results were published in the Proceedings of the American Society for Clinical Oncology's Annual Meeting being held currently in Atlanta, GA. The mAb 806 is an investigational drug and it is not approved for use in any indication in any country at this time.
Ludwig Institute for Cancer Research
Antibody Current Events and Antibody News RSSNew findings suggest strategy to help generate HIV-neutralizing antibodies
New discoveries about anti-HIV antibodies may bring researchers a step closer to creating an effective HIV vaccine, according to a new paper co-authored by scientists at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Sweet -- sugared polymer a new weapon against allergies and asthma
Scientists at Johns Hopkins and their colleagues have developed sugar-coated polymer strands that selectively kill off cells involved in triggering aggressive allergy and asthma attacks.
UAB Researchers Discover Antibody Receptor Identity, Propose Renaming Immune-System Gene
Researchers at the University of Alabama at Birmingham (UAB) have uncovered the genetic identity of a cellular receptor for the immune system's first-response antibody, a discovery that sheds new light on infection control and immune disorders.
UCLA researchers create 'fly paper' to capture circulating cancer cells
Just as fly paper captures insects, an innovative new device with nano-sized features developed by researchers at UCLA is able to grab cancer cells in the blood that have broken off from a tumor.
Aileron collaborates study in Nature: Stapled peptides inhibit Notch1 transcription factor
This research validates the potential for Stapled Peptides to modulate key intracellular biological targets, such as transcription factors, that have not been addressable with current small molecule or biologic drug modalities.
Scientists explain binding action of 2 key HIV antibodies; could lead to new vaccine design
A very close and detailed study of how the most robust antibodies work to block the HIV virus as it seeks entry into healthy cells has revealed a new direction for researchers hoping to design an effective vaccine.
Researchers find new way to attack inflammation in Graves' eye disease
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab.
First use of antibody and stem cell transplantation to successfully treat advanced leukemia
For the first time, researchers at Fred Hutchinson Cancer Research Center have reported the use of a radiolabeled antibody to deliver targeted doses of radiation, followed by a stem cell transplant, to successfully treat a group of leukemia and pre-leukemia patients for whom there previously had been no other curative treatment options.
New Synthetic Molecules Trigger Immune Response to HIV and Prostate Cancer
Researchers at Yale University have developed synthetic molecules capable of enhancing the body's immune response to HIV and HIV-infected cells, as well as to prostate cancer cells. Their findings, published online in the Journal of the American Chemical Society, could lead to novel therapeutic approaches for these diseases.
Common Pain Relievers May Dilute Power of Flu Shots
With flu vaccination season in full swing, research from the University of Rochester Medical Center cautions that use of many common pain killers - Advil, Tylenol, aspirin - at the time of injection may blunt the effect of the shot and have a negative effect on the immune system.
More Antibody Current Events and Antibody News Articles
 |
Antibodies: A Laboratory Manual by Ed Harlow (Author), David Lane (Author) Introduction to immunochemistry for molecular biologists and other nonspecialists. Spiral. |
 |
Antibody Starring: Robin Givens, Lance Henriksen, William Zabka, Gastón Pauls, Julian Vergov Directed By: Christian McIntire Also With: Adolfo Bartoli (Cinematographer), Scott Clausen (Composer), Christian McIntire (Editor) A terrorist has a nuclear bomb detonator microchip hidden inside his body. Now, security expert Richard Gaynes and a team of scientists will use an experimental craft to enter his bloodstream. It's a race against time to track down and destroy the detonator. The fate of the world hangs in the balance. |
 |
Therapeutic Monoclonal Antibodies: From Bench to Clinic by Zhiqiang An (Editor) 70-chapter authoritative reference that covers therapeutic monoclonal antibody discovery, development, and clinical applications while incorporating principles, experimental data, and methodologies. First book to address the discovery and development of antibody therapeutics in their entirety. Most chapters contain experimental data to illustrate the principles described in them. Authors provide detailed methodologies that readers can take away with them and use in their own laboratories |
 |
Antibodies (Two-Disc Special Edition) Starring: Norman Reedus, Christian von Aster, André Hennicke, Waltraud Witte, Konstantin Graudus Directed By: Christian Alvart Studio: Mpi Home Video Release Date: 08/28/2007 Run time: 128 minutes |
 |
Making and Using Antibodies: A Practical Handbook by Gary C. Howard (Editor), Matthew R. Kaser (Editor) Antibodies are an indispensable tool in the study of biology and medicine. Making and Using Antibodies: A Practical Handbook presents techniques in a single, comprehensive source for the production and use of antibodies. It enables researchers to immediately access lab-tested, proven protocols. Written and edited by an elite team of scientists, who have developed and refined many of the methods, this book covers- Commercially available adjuvants designed for the production of antisera in the research setting Methods for the production, purification, and characterization of antibodies Practical guidance to researchers needing to modify antibodies Basic techniques including enzyme-linked immunosorbent assay (ELISA), Western blotting, immunohistochemistry, and flow... |
 |
Therapeutic Antibodies: Methods and Protocols (Methods in Molecular Biology) by Antony S. Dimitrov (Editor) With revenues from the top five therapeutic antibodies accounting for a majority of the recent pharmaceutical sales, the research and development in the field has exploded over the past several years and is expected to grow with new emerging monoclonal antibodies like Numax, Lucentis, Actemra, and others. In Therapeutic Antibodies: Methods and Protocols, leading experts from academic laboratories and biotechnology companies present an extensive set of protocols for the discovery and development of therapeutic antibodies, featuring sections devoted to recombinant antigens, antibody libraries, antibody discovery, antibody engineering, and antibody preclinical development. Written in the highly successful Methods in Molecular Biology™ series format, the chapters contain brief... |
 |
Antibody Starring: Max Allan, Velizar Binev, Victor Braun (II), Nick Brennen, Val Constance |
|
Fisherbrand Frosted Fluorescent Antibody MicroSlides; Two Rings with 15mm Diameter; Size: 1 x 3 in. by Fisher Scientific Slide, Microscope; Fisherbrand; Frosted fluorescent antibody; Two rings with 15mm dia.; Size: 1 x 3 in. (25 x 75mm); Thickness: 0.97 to 1.07mm; 144/pk.; 10/cs. | |
|
Human Antibodies by Ios Press | |
 |
Handbook of Therapeutic Antibodies 3-Volume Set by Stefan Dübel (Editor) In this most comprehensive reference source for the development, production and therapeutic application of antibodies, Volume I contains general chapters presenting established technologies and clinical applications. Volume II provides a look at emerging technologies, new therapeutic concepts, and clinical studies. The third volume features detailed and specific information about each currently approved type of antibody, including the clinical data. A must-have resource for academic researchers, decision makers in industry and healthcare professionals in the clinic. |
| © 2009 BrightSurf.com |